DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
Aktueller Standort:
> This Story

Forward Printable StoryPrint Comment




Molecular Imaging Homepage

Eden Radioisotopes secures reactor project funding for medical isotope production

MILabs selected by Columbia University Irving Medical Center for upgrades to its molecular imaging capabilities

Blue Earth Diagnostics continues to expand access to Axumin (fluciclovine (18F)) in Europe

NRC calls for additional feedback on training and experience requirements for radiopharmaceuticals requiring a written directive

SHINE breaks ground on medical isotope production facility

MR Solutions' PET/MRI scanner explores innovative magnetic nanoparticles as a bimodal imaging agent

ITM builds new production site in Munich area

NorthStar Medical closes $100 million financing with Oberland Capital to expand domestic Mo-99 radioisotope production capacity

SNMMI and ACR collaborate on clinical data registry for nuclear medicine

New PET imaging biomarker could better predict progression of Alzheimer's disease

Zionexa completes a second $5 million capital raise

Press releases may be edited for formatting or style
New York, N.Y (USA) and Paris (France), April 11, 2019 – Zionexa, a radiopharmaceutical company specialized in the development and commercialization of innovative molecular imaging companion diagnostics (CDx) for targeted therapies in oncology, announced today that it has completed a second capital raise of $5 Million via two French investment funds, iXO Private Equity and SofiMac, as well as Denos, its majority shareholder.

This funding has been realized in line with Zionexa’s initial 2018 plan in order to raise a total of $10 Million with the first 12 months in order to register with the FDA (Food and Drug Administration), its first pipeline molecule, EstroTep, an innovative biomarker for targeted in-vivo diagnostic of metastatic breast cancer.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED

These additional funds will also enable Zionexa to further develop its pipeline of other innovative molecules, notably with the launch of multicentric Phase III clinical trials in Europe that Zionexa will sponsor. A more significant third fundraising is planned within the next 12 months, to finance the commercial launches of EstroTep, in the U.S. and France.

Bernard Landes, CEO at Zionexa, comments: “This second fundraising will allow us to accelerate the launch of EstroTep and further develop our pipeline of targeted biomarkers for early and specific cancer diagnostic. Today, many patients follow heavy and often inadequate treatments. Our objective is to give clinicians access to innovative companion diagnostics tracers, in order for them to use these tracers in real life and contribute to improve the quality of their patient’s pathway. EstroTep, our first innovative companion diagnostic tracer has demonstrated its relevance in multiple clinical trials around the world.”

Baptiste Martin-Wurmser, Investment Director at IXO Private Equity adds:” Medical Imaging is a priority investment area for IXO Private Equity. Zionexa, specialized in molecular imaging, successfully develops new molecules that meet various needs: it helps clinicians better monitor patients’ disease and treatments, notably by evaluating their effectiveness. This has been key in our decision to invest in such an early stage project as well as the fact that we already knew the management team and its quality.”

Cécile Thébault, Associate Investments Director at Sofimac, further comments:” We are very glad to support this company which has key advantages in a high potential sector, especially in the U.S. Zionexa has an international and complementary team of experts, that bring a comprehensive know-how to the company, in terms of development, regulatory and market access of radiopharmaceuticals. Zionexa’s, ambitious pipeline, includes a first very promising molecule, EstroTep, that might be commercialized within 12 months.”
  Pages: 1 - 2 >>

Molecular Imaging Homepage

You Must Be Logged In To Post A Comment

Erhöhen Sie Ihren Bekanntheitsgrad
Auktionen + Privatverkäufe
Den besten Preis erzielen
Geräte/Geräteteile kaufen
Den günstigsten Preis finden
Daily News
Die neuesten Nachrichten lesen
Alle DOTmed Benutzer durchsuchen
Ethik auf DOTmed
Unseren Ethik-Standard anzeigen
Gold-Parts Verkäufer-Programm
PH-Anfragen erhalten
Gold Service Dealer-Programm
Anfragen empfangen
Alle Gesundheitsdienstleister-Tools anzeigen
Einen Job suchen
Parts Hunter +EasyPay
Angebote für Geräteteile erhalten
Kürzlich zertifiziert
Kürzlich zertifizierte Benutzer anzeigen
Kürzlich bewertet
Kürzlich zertifizierte Benutzer anzeigen
Rental Central
Geräte billiger mieten
Geräte/Geräteteile verkaufen
Das meiste Geld erhalten
Service-Techniker Forum
Hilfe und Beratung finden
Einfache Angebots-Anfrage
Angebote für Geräte erhalten
Virtuelle Messe
Service für Geräte finden
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to, Inc. Copyright ©2001-2019, Inc.